Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Nivolumab plus cabozantinib as first-line treatment for advanced clear cell renal cell carcinoma was consistently superior to sunitinib across all subgroups studied
Findings from the PRINCEPS study
CheckMate 238 results at 4-years consistently favour nivolumab across all parameters evaluated
Final overall survival analysis of the nextMONARCH study
Relapse-free interval rates in TOSCA study were poorer in elderly compared with younger patients
Findings from the WIDE study
Gustave Roussy Molecular Tumour Board stratify the genomic alterations detected in tissue/liquid biopsy based on ESCAT
Time to deterioration on several key functioning scales in KEYNOTE-177 was longer with pembrolizumab
Interim results of the phase III JAVELIN head & neck 100 study in locally advanced squamous cell carcinoma of the head and neck
Findings from the IFCT-1601 IONESCO study
Rapid biochemical and structural response to the treatment with infigratinib
Findings from the phase III study of pharmacological prevention in patients with familial adenomatous polyposis
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
